Alzheimer DiseasePhase 1NCT04133454
Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT
A Phase 1 study testing AAV-hTERT in people with Alzheimer Disease, run by Libella Gene Therapeutics at 1 site in Colombia.
Trial summary
Using gene therapy to express active telomerase (hTERT) in human cells has the potential to treat many neurodegenerative diseases related to aging, including Alzheimer's disease (AD). This study will entail treating subjects with hTERT delivered via transduction using AAV. Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Alzheimer Disease
- What is being tested?
- AAV-hTERT
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteColombia
- Study dates
- 10 Oct 2019to Jan 2021
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects must meet the following inclusion criteria at the screening visit.
- Age of 45 years or older.
- Clinical diagnosis of Alzheimer's disease or early signs of dementia.
- Subjects, or their authorized representatives, must be adequately informed and understand the nature and risks of the study and must be able to provide a signature and date in the Informed Consent Form (ICF).
- Women must undergo a negative serum pregnancy test at the screening assessment.
- Subjects, or their representatives, must be able to communicate effectively with the study staff.
- Subjects, or their authorized representatives, must certify that they are able and willing to follow all protocol requirements and study restrictions.
Who cannot join
- Subjects are not eligible for the study if they meet any of the following criteria at the screening visit, unless otherwise specified.
- Subjects who have a history of allergy, hypersensitivity, or intolerance to any medications, components, or excipients of the investigational product, which cannot be resolved by the staff conducting the study.
- Female subjects who are pregnant, expected to become pregnant, or lactating/nursing.
- Subjects who are sexually active and who are unwilling or unable to use a method of effective contraception (e.g., hormonal and/or barrier) during their participation in the study.
- Subjects who are intolerant of, or do not wish to receive, IV or IT injections.
- Subjects who are currently alcoholics and/or use psychoactive substances.
Show all 12Show fewer
- Subjects who cannot tolerate venipuncture and/or venous access.
- Subjects who have donated or had a significant loss of whole blood (480 ml or more) within 30 days, or donated plasma or platelets within 14 days prior to screening.
- Subjects who have received blood or blood products within 30 days prior to screening.
- Subjects who have been treated with another research product 30 days prior to the screening assessment, or plan to participate in another clinical trial, while in this study if in the opinion of the principal investigator, may place the subject at risk due to participation in the study, or may influence the results of the study or the subject's ability to complete the study. If more than 30 days have passed since participation in another clinical trial, the study staff must ensure that the subject has recovered from any adverse event (AE) associated with the research product used.
- Subjects who have a history or evidence of active infection or febrile illness within 7 days prior to the screening assessment.
- Subjects who have a history of any other clinically significant disease or disorder that, in the opinion of the principal investigator, may place the subject at risk due to participation in the study, or may influence the results of the study or the subject's ability to complete the study.
Trial locations and contacts
1 site in 1 country.
Colombia1 site, 1 recruiting
- Recruiting
IPS Arcasalud SAS
Zipaquirá, Cundinamarca, 250251
Wiston Pernet, MD, 57 3006840951, wirapeca@gmail.com
Jorge Ulloa, MD
About this study
Official title: Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Alzheimer's Disease: AAV- hTERT
Using gene therapy to express active telomerase (hTERT) in human cells has the potential to treat many neurodegenerative diseases related to aging, including Alzheimer's disease (AD).
This study will entail treating subjects with hTERT delivered via transduction using AAV. The goal is to extend the telomeres to prevent, delay, or even reverse the development of the pathology of AD. It is expected to have a direct consequence on cognitive function and quality of life in patients with neurodegenerative diseases, such as AD.
Read the detailed description
Patients diagnosed with AD who meet with the inclusion - exclusion criteria, will be treated with a single dose of LGT delivered intravenously (IV) and intrathecally (IT).
Baseline will be performed within 8 weeks of beginning the treatment regimen. The treatment regimen will begin with IV delivery of AAV-hTERT, defined as "Day 0." Safety and efficacy analyses will be conducted at Weeks 1, 4, 13, 26, 39, and 52 post-treatment.
Study objectives
Primary: Safety and Tolerability
- Investigate the safety and tolerability of AAV-hTERT by IV and IT administration.
Secondary: Provisional Efficacy
- Investigate LGT's ability to deliver hTERT to human cells and lengthen telomeres.
- Investigate the effects of lengthening telomeres on AD.
- Investigate other benefits provided by lengthening telomeres.
- Conditions
- Alzheimer Disease
- Being tested
- AAV-hTERT
- Keywords
- Cognition Disorders, Alzheimer Disease, AAV, Dementia, Gene therapy, telomere, telomerase
- Medical subject headings
- Alzheimer Disease, Cognition Disorders, Dementia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AAV-hTERTDrug
Also called LGT
subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration
| Study group | Role | What they receive |
|---|---|---|
| subjects treated with LGT | Experimental | subjects will be treated with a single dose of LGT (AAV-hTERT) Receives: Drug: AAV-hTERT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of adverse events
Incidence of serious adverse events and adverse events throughout the study
Measured: 12 months
Secondary outcomes (1)
hTERT expression and telomerase activity
Change from baseline of the telomere length
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2019
- Study start10 Oct 2019
- Primary completionJan 2021 (estimated)
- Study completionJan 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 5 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Libella Gene Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jorge Ulloa, MD, Principal investigator, IPS Arcaslud SAS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04133454
- Sponsor's protocol ID
- Libella CO-02
- Status last verified
- Oct 2019
- First submitted
- 28 Dec 2017
- Last updated
- 28 Oct 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Alzheimer's Disease: AAV- hTERT
- ClinicalTrials.gov ID
- NCT04133454
- Acronym / sponsor ID
- Libella CO-02
- Conditions
- Alzheimer Disease
- Keywords
- Cognition Disorders, Alzheimer Disease, AAV, Dementia, Gene therapy, telomere, telomerase
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 5 participants (estimated)
- Lead sponsor
- Libella Gene TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- 10 Oct 2019 (actual)
- Primary completion
- Jan 2021 (estimated)
- Study completion
- Jan 2021 (estimated)
- First posted
- 21 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Using gene therapy to express active telomerase (hTERT) in human cells has the potential to treat many neurodegenerative diseases related to aging, including Alzheimer's disease (AD).
This study will entail treating subjects with hTERT delivered via transduction using AAV. The goal is to extend the telomeres to prevent, delay, or even reverse the development of the pathology of AD. It is expected to have a direct consequence on cognitive function and quality of life in patients with neurodegenerative diseases, such as AD.
Detailed description
Patients diagnosed with AD who meet with the inclusion - exclusion criteria, will be treated with a single dose of LGT delivered intravenously (IV) and intrathecally (IT).
Baseline will be performed within 8 weeks of beginning the treatment regimen. The treatment regimen will begin with IV delivery of AAV-hTERT, defined as "Day 0." Safety and efficacy analyses will be conducted at Weeks 1, 4, 13, 26, 39, and 52 post-treatment.
Study objectives
Primary: Safety and Tolerability
- Investigate the safety and tolerability of AAV-hTERT by IV and IT administration.
Secondary: Provisional Efficacy
- Investigate LGT's ability to deliver hTERT to human cells and lengthen telomeres.
- Investigate the effects of lengthening telomeres on AD.
- Investigate other benefits provided by lengthening telomeres.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| subjects treated with LGT | Experimental | Drug: AAV-hTERTsubjects will be treated with a single dose of LGT (AAV-hTERT) |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Subjects must meet the following inclusion criteria at the screening visit.
- Age of 45 years or older.
- Clinical diagnosis of Alzheimer's disease or early signs of dementia.
- Subjects, or their authorized representatives, must be adequately informed and understand the nature and risks of the study and must be able to provide a signature and date in the Informed Consent Form (ICF).
- Women must undergo a negative serum pregnancy test at the screening assessment.
Key exclusion criteria (12 listed)
- Subjects are not eligible for the study if they meet any of the following criteria at the screening visit, unless otherwise specified.
- Subjects who have a history of allergy, hypersensitivity, or intolerance to any medications, components, or excipients of the investigational product, which cannot be resolved by the staff conducting the study.
- Female subjects who are pregnant, expected to become pregnant, or lactating/nursing.
- Subjects who are sexually active and who are unwilling or unable to use a method of effective contraception (e.g., hormonal and/or barrier) during their participation in the study.
- Subjects who are intolerant of, or do not wish to receive, IV or IT injections.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AAV-hTERTAlso: LGTsubjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration | Drug | subjects treated with LGT |
Primary outcome
Incidence of adverse events
Time frame: 12 months
Incidence of serious adverse events and adverse events throughout the study
1 secondary outcome
hTERT expression and telomerase activity
Time frame: 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2019.
- Individual participant dataSharing planned: No
Related trials for Alzheimer Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jorge Ulloa, MD principal investigator
IPS Arcaslud SAS
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing AAV-hTERT in people with Alzheimer Disease, run by Libella Gene Therapeutics at 1 site in Colombia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jeff Mathis, PhD (1 785 4100223, jmathis@libellagt.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of adverse events (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2019.